Trial Profile
A Phase II/III, Multicenter, Randomized, Open Label, Active Controlled, Clinical Study to Assess the Immunogenicity and Safety of Tetanus Toxoid, Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine Manufactured by Serum Institute of India Pvt. Ltd (SIIPL) in Comparison with Boostrix Vaccine of GSK in Healthy Adults, Adolescents and Children in India
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 13 Nov 2018
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Serum Institute of India
- 13 Nov 2018 New trial record